The use of trastuzumab and other monoclonal antibodies directed at HER2, such as pertuzumab, has resulted in markedly improved prognosis for women with HER2-positive breast cancers, both by prolonging survival in advanced, metastatic disease and by reducing the risk for cancer recurrence in the adjuvant setting. This evidence concerns the gene ERBB2 and metastatic neoplasm.